Needham Reiterates Buy on Inari Medical, Maintains $72 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson reiterated a Buy rating on Inari Medical (NASDAQ:NARI) and maintained a $72 price target.
March 06, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson reiterated a Buy rating on Inari Medical and maintained a $72 price target.
The reiteration of a Buy rating and maintenance of a $72 price target by a reputable analyst suggests a positive outlook for Inari Medical's stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100